MedTrace Logo

Retrospective Review of Proliferative Diabetic Retinopathy Patients

NCT03609996 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-02-07

No results posted yet for this study

Summary

The primary objective of the protocol is to determine if intravitreal ranibizumab alone decreases retinal neovascularization from Proliferative Diabetic Retinopathy (PDR) with deferred panretinal photocoagulation (PRP) and/or vitrectomy at one year after treatment with ranibizumab has been initiated.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DEVICE

Panretinal Photocoagulation

Laser treatment for PDR

DRUG

Lucentis

Intraviteral injection

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Elman Retina Group

    lead OTHER

Principal Investigators

  • Michael Elman · Elman Retina Group, P.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-12-01
Completion
2019-12-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609996 on ClinicalTrials.gov